Identification of novel hub genes and pathways predictive of fibrosis progression in cancer-related lymphedema through integrated multi-omics.
Chen J., Chen Y., Wang L., Deng Y., Zhou Y., Wang Y.
Laboratory Study on Scar, published in Front Immunol (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Front Immunol (2025)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40881699
- PMCID
- PMC12380543
- DOI
- 10.3389/fimmu.2025.1625972
- Citations
- 1
Abstract (original English)
Background Cancer-related lymphedema (CRL) is a common chronic complication following cancer treatment, characterized by impaired lymphatic drainage, interstitial fluid retention, and progressive fibrosis. Although the mechanisms of hypertrophic scar (HTS) fibrosis have been extensively investigated, the molecular drivers of fibrosis in CRL remain unclear. Identification of reliable biomarkers and novel therapeutic targets is essential for enabling early intervention. Methods Transcriptomic datasets of CRL and HTS from the Gene Expression Omnibus (GEO) were integrated to identify fibrosis-associated differentially expressed genes (DEGs) and construct co-expression modules. Weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network analysis were employed to nominate hub genes. Single-cell RNA sequencing (scRNA-seq) data were used to localize candidate gene expression within immune and mesenchymal cell populations. The most promising biomarker was validated in clinical CRL tissues by Masson's trichrome staining and Western blotting, and Pearson correlation analyses were performed to assess its association with collagen deposition and disease duration. Results A total of 154 fibrosis-related genes were found to be shared by CRL and HTS. Among them, Asporin (ASPN) emerged as the most promising hub gene, with markedly elevated expression in la
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Clinical Applications of Autologous Fat Grafting in Pathological Hand Conditions.
Systematic Review with a reported sample of 7 on Osteoarthritis, Scar, published in J Hand Surg Asian Pac Vol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 7
J Hand Surg Asian Pac Vol - Level AMeta-analysisPubMed
Stem cell therapy in thin endometrium and Asherman's syndrome: a systematic review and meta-analysis.
Meta-analysis with a reported sample of 323 on Scar, published in Eur J Obstet Gynecol Reprod Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 323
Eur J Obstet Gynecol Reprod Biol - Level AMeta-analysisEurope PMC
Therapeutic value of mesenchymal stem cell-derived extracellular vesicles in hypertrophic and keloid scars: a systematic review and meta-analysis
Meta-analysis on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
Front Cell Dev Biol - Level AMeta-analysisPubMed
Efficacy and safety of autologous cell-based therapies for atrophic acne scar treatment: an updated systematic review and meta-analysis with in-depth methodological and clinical insights.
Meta-analysis with a reported sample of 500 on Chronic Wound, Scar, published in Front Cell Dev Biol (2026) — summary generated from the PubMed abstract.
- 2026
- n = 500
Front Cell Dev Biol - Level ASystematic ReviewEurope PMC
Comparative Efficacy and Safety of Fractional CO<sub>2</sub> Laser and Gold Microneedling Radiofrequency for Atrophic Acne Scars: A Systematic Review
Systematic Review on Chronic Wound, Scar, published in Skin Res Technol (2026) — summary generated from the PubMed abstract.
- 2026
Skin Res Technol - Level AMeta-analysisPubMed
Role of exosome therapy in reconstructive surgery: a review.
Meta-analysis on Chronic Wound, Scar, Immune Modulation, published in Front Med (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Med (Lausanne)1 citations